MedTrace Logo

Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA)

NCT02739763 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2016-05-30

No results posted yet for this study

Summary

The investigators wish to understand how resistance to malaria develops and how this affects the growth rate of malaria in individuals who have past exposure to malaria.

Conditions

Interventions

BIOLOGICAL

Plasmodium falciparum sporozoite (PfSPZ)

Plasmodium falciparum sporozoites

Sponsors & Collaborators

  • KEMRI-Wellcome Trust Collaborative Research Program

    collaborator OTHER

  • Sanaria Inc.

    collaborator INDUSTRY

  • KEMRI Centre for Clinical Research

    collaborator UNKNOWN

  • Pwani University

    collaborator UNKNOWN

  • University of Cambridge

    collaborator OTHER

  • Wellcome Sanger Institute

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Philip Bejon, MD,PhD · KEMRI Wellcome Trust Research Programme and University of Oxford

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2020-01-31
Completion
2020-11-30

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02739763 on ClinicalTrials.gov